Tissue regeneration leaves the experimental field to enter clinical practice. In Lille, LATTICE MEDICAL embodies this transition with a pioneering approach which consists of reproducing the natural process of breast tissue reconstruction using a 3D printed biodegradable implant. The company is developing a new generation of medical devices capable of lastingly replacing traditional implants.
Its flagship innovation, MATTISSE, in clinical trials in seven hospital centers in France and Spain, is based on the principle of allowing the body to regenerate itself. The implant, designed from resorbable biomaterials, serves as a temporary matrix, and gradually degrades as the patient’s cells rebuild autologous tissue, free of foreign bodies in the long term. This approach aims to offer women who have undergone a mastectomy a more natural and less invasive solution than silicone prostheses.
Beyond medical prowess, LATTICE MEDICAL is reaching an industrial milestone, the company is developing in Lille a production tool integrating 3D printing, biomaterials and a clean room, capable of ensuring the manufacturing of its devices and offering a subcontracting offer via Lattice Services. This infrastructure positions the company as one of the first French players capable of producing on a clinical scale in the field of regenerative medicine.
“This fundraising is a real turning point for Lattice Medical. It allows us to pursue our mission: to reinvent tissue reconstruction after cancer, while building an innovative and industrial French medtech, which contributes to the health of the territory and the quality of life of patients,” underlines Julien PayenCEO of LATTICE MEDICAL.
The company is already preparing to extend its technology to other reconstructive uses, notably with RODINa matrix intended for large defects in subcutaneous tissues. Drawing on the principles of tissue engineering, LATTICE MEDICAL paves the way for more sustainable restorative medicine, anchored in local production and industrial sovereignty.
The company, founded in 2017, relies on the collaboration of surgeons, biologists and textile engineers. Since 2020, it has produced its devices in Wervicq-Sud, favoring short circuits.
LATTICE MEDICAL has lifted 43 million euros in Series Bone of the most important operations of the year for French medtech. The operation is carried out by the SPI Fundmanaged on behalf of the State within the framework of France 2030 by Bpifrancewith the support of Blast.Club, Sprim, TIDJEEas well as historical investors EIC Fund, Captech Health, Nord France Priming And FIRA North East. It also includes non-dilutive financing provided by banking partners and programs M3DINPRINT And LIPOTEC.
